Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently
approved to treat patients with B-cell malignancies, including Waldenström …

Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA),
this Australasian Leukaemia & Lymphoma Group translational study sought to characterize …

Disease overview Marginal zone lymphomas (MZL) are collectively the second most
common type of indolent lymphoma. Diagnosis Three subtypes of MZL are recognized …

Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the
treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib …

Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas
and include 3 different subtypes—namely, extranodal (EMZL), nodal, and splenic (SMZL) …

Although mostly incurable, indolent non-Hodgkin lymphomas (iNHL) are chronic diseases
with a median overall survival approaching 20 years. In recent years, important advances in …

Marginal zone lymphoma (MZL) is an indolent type of non‐Hodgkin lymphoma that develops
through pathological B cell receptor signaling. Orelabrutinib, a new‐generation oral small …

Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B
lymphocytes and has been a crucial therapeutic target of several generations of kinase …

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in
patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 …